Pirfenidone for Radiation-Induced Fibrosis
Author Information
Author(s): Simone Nicole L, Soule Benjamin P, Gerber Lynn, Augustine Elizabeth, Smith Sharon, Altemus Rosemary M, Mitchell James B, Camphausen Kevin A
Primary Institution: National Cancer Institute, National Institutes of Health
Hypothesis
Can Pirfenidone ameliorate established radiation-induced fibrosis in patients?
Conclusion
Pirfenidone may benefit patients with radiation-induced fibrosis and is worthy of a larger well-controlled trial.
Supporting Evidence
- Seven patients were enrolled, with five completing the study.
- Six out of seven patients showed improved range of motion during treatment.
- Patients reported subjective improvements in mobility and daily activities.
Takeaway
This study tested a medicine called Pirfenidone to see if it could help people who had problems from radiation treatment. Some people felt better after taking it.
Methodology
Open label, prospective pilot study administering 800 mg of Pirfenidone three times a day to patients with established radiation-induced fibrosis.
Potential Biases
Potential bias due to subjective reporting and lack of blinding.
Limitations
Small sample size and subjective measures of improvement.
Participant Demographics
Seven male patients aged 53 to 60, with four treated for head and neck cancer and one for Hodgkin's Disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website